Antigen-binding molecules and uses thereof
OwnerSamantha J. BUSFIELD, Matthew J. WILSONinventors
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to an antigen-binding molecule that specifically binds to interleukin-31 (IL-31), wherein the antigen-binding molecule comprises an immunoglobulin heavy chain variable domain and an immunoglobulin light chain variable domain.
Claims53
An antigen-binding molecule that specifically binds to interleukin-31 (IL-31), wherein the antigen-binding molecule comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein the VH comprises a complementarity determining region 1 (VH CDR1) comprising the amino acid sequence of SEQ ID NO:
- 6 or an amino acid sequence having at least 80% sequence identity thereto, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:
- 7 or an amino acid sequence having at least 80% sequence identity thereto and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:
- 8 or an amino acid sequence having at least 80% sequence identity thereto;
- and wherein the VL comprises a complementarity determining region 1 (VL CDR1) comprising the amino acid sequence of SEQ ID NO:
- 9 or an amino acid sequence having at least 80% sequence identity thereto, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:
- 10 or an amino acid sequence having at least 80% sequence identity thereto, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
- 11 or an amino acid sequence having at least 80% sequence identity thereto, wherein the amino acid sequences of the CDR are based on IMGT numbering.
An antigen-binding molecule that specifically binds to an epitope of canine IL-31 comprising amino acid residues L29, Y32, Q33 and P40 of SEQ ID NO:1.
An immunogenic composition capable of raising an immune response to IL-31, wherein the composition comprises (i) an immunogen comprising a B cell epitope of IL-31 and (ii) a pharmaceutically acceptable carrier, wherein the B cell epitope comprises an amino acid sequence corresponding to amino acid positions 29-40 of SEQ ID NO:1, or an amino acid sequence that has at least 80% sequence identity thereto, and wherein the immunogen does not comprise the amino acid sequence of a native IL-31 molecule.
Dependencies are inferred from the claim text.